



(11) **EP 3 496 724 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
17.11.2021 Bulletin 2021/46

(45) Date of publication and mention
of the grant of the patent:
06.10.2021 Bulletin 2021/40

(21) Application number: **17840401.8**

(22) Date of filing: **14.08.2017**

(51) Int Cl.:
C07D 471/14^(2006.01) A61K 31/519^(2006.01)
A61P 35/00^(2006.01)

(86) International application number:
PCT/US2017/046715

(87) International publication number:
WO 2018/031987 (15.02.2018 Gazette 2018/07)

(54) **PROTEIN KINASE REGULATORS**
PROTEINKINASEREGULATOREN
RÉGULATEURS DE PROTÉINE KINASES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **12.08.2016 US 201662374399 P**

(43) Date of publication of application:
19.06.2019 Bulletin 2019/25

(73) Proprietors:
• **Madera Therapeutics, LLC**
Cary, NC 27513 (US)
• **Iwanowicz, Edwin, J.**
Cary, North Carolina 27513 (US)

(72) Inventor: **IWANOWICZ, Edwin, J.**
Cary, North Carolina 27513 (US)

(74) Representative: **Winter, Brandl - Partnerschaft**
mbB
Alois-Steinecker-Straße 22
85354 Freising (DE)

(56) References cited:
EP-A1- 3 315 498 WO-A1-2016/123183
WO-A1-2016/123571 CN-A- 104 860 948
US-A1- 2008 206 312 US-A1- 2012 115 875

EP 3 496 724 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
